SAM
TEVA icon

Silphium Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Silphium Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-45,000
Closed -$769K – 135
2018
Q1 		$769K Buy
+45,000
New +$879K 0.42% 35

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Silphium Asset Management's TEVA Position: Q2 2018 in Review

Silphium Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2018, closing a stake of 45,000 shares — an estimated $769K sold.

Silphium Asset Management first reported a position in TEVA in Q1 2018 and held it in 1 quarter. The position peaked at $769K in Q1 2018. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2018.

  • Silphium Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Silphium Asset Management sold 45,000 Teva Pharmaceuticals shares in Q2 2018, an estimated $769K.
  • Silphium Asset Management first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Silphium Asset Management's Teva Pharmaceuticals position peaked at $769K in Q1 2018.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2018.

Based on Silphium Asset Management's 13F filing for Q2 2018, filed 30 Jan 2025.